Relevant bibliographies by topics / Pharmaceutical policy. Pharmacy

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Pharmaceutical policy. Pharmacy'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pharmaceutical policy. Pharmacy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pharmaceutical policy. Pharmacy"

1

Traulsen, Janine M., and Anna Birna Almarsdóttir. "Pharmaceutical Policy and the Pharmacy Profession*." Pharmacy World & Science 27, no. 5 (October 2005): 359–63. http://dx.doi.org/10.1007/s11096-005-3798-y.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kazaryan, Irina. "Assessment of the pharmaceutical policy framework." Research in Social and Administrative Pharmacy 14, no. 8 (August 2018): e40. http://dx.doi.org/10.1016/j.sapharm.2018.05.072.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Babar, Zaheer-Ud-Din, and Shazia Jamshed. "Social pharmacy strengthening clinical pharmacy: why pharmaceutical policy research is needed in Pakistan?" Pharmacy World & Science 30, no. 5 (August 7, 2008): 617–19. http://dx.doi.org/10.1007/s11096-008-9246-z.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zgarrick, David P. "Research Methods for Pharmaceutical Practice and Policy." Research in Social and Administrative Pharmacy 11, no. 3 (May 2015): e148-e149. http://dx.doi.org/10.1016/j.sapharm.2011.05.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Nagaria, Raveena Amee, Syed Shahzad Hasan, and Zaheer-Ud-Din Babar. "Pharmacy, pharmaceuticals and public policy: Solving the puzzle." Research in Social and Administrative Pharmacy 16, no. 6 (June 2020): 840–43. http://dx.doi.org/10.1016/j.sapharm.2019.07.010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ashker, Sumer, and Jill S. Burkiewicz. "Pharmacy residents’ attitudes toward pharmaceutical industry promotion." American Journal of Health-System Pharmacy 64, no. 16 (August 15, 2007): 1724–31. http://dx.doi.org/10.2146/ajhp060576.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Jones, Erika JM, Neil J. MacKinnon, and Ross T. Tsuyuki. "Pharmaceutical Care in Community Pharmacies: Practice and Research in Canada." Annals of Pharmacotherapy 39, no. 9 (September 2005): 1527–33. http://dx.doi.org/10.1345/aph.1e456.

Full text
Abstract:
OBJECTIVE: To discuss the provision of pharmaceutical care in community pharmacies in Canada including the following topics: organization and delivery of health services, health service policy, methods of payment, types of pharmacy services provided, types of cognitive pharmacy services, research in community pharmacy, and future plans for community pharmacy services. DATA SYNTHESIS: The implementation of pharmaceutical care in Canadian community pharmacies continues to become more widespread. However, barriers to the provision of pharmaceutical care still exist, including the current shortage of pharmacists and lack of reimbursement systems for cognitive services. Evidence of the value of pharmaceutical care in Canadian community pharmacies has been supported by several pharmacy practice research projects. The pharmacist's role in patient care is expected to continue to expand. CONCLUSIONS: Although Canadian pharmacists' capabilities are not yet universally recognized and applied to their full potential, there is reason to be optimistic about the future of pharmaceutical care in the community setting in Canada.
APA, Harvard, Vancouver, ISO, and other styles
8

Hermansyah, Andi, Luh Wulandari, Susi A. Kristina, and Sherly Meilianti. "Primary health care policy and vision for community pharmacy and pharmacists in Indonesia." Pharmacy Practice 18, no. 3 (July 22, 2020): 2085. http://dx.doi.org/10.18549/pharmpract.2020.3.2085.

Full text
Abstract:
The practice of community pharmacy in low and middle-income countries, including in Indonesia, is often described as in the state of infancy with several intractable barriers that have been substantially and continuously hampering the practice. Such description might be valid in highlighting how pharmacy is practiced and the conditions within and beyond community pharmacy organizations. Therefore, it is not surprising that the concept of integrating community pharmacy into the primary care system may not be considered in the contemporary discourse despite the fact that community pharmacy has been operating within communities for years. However, in the case of Indonesia, we argue that changes in the health care system within the past decade particularly with the introduction of the universal health coverage (UHC) in 2014, may have significantly amplified the role of pharmacists. There is good evidence which highlights the contribution of pharmacist as a substantial health care element in primary care practice. The initiative for employing pharmacist, identified in this article as primary care pharmacist, in the setting of community health center [puskesmas] and the introduction of affiliated or contracted community pharmacy under the UHC have enabled pharmacist to work together with other primary care providers. Moreover, government agenda under the “Smart Use of Medicines” program [Gema Cermat] recognizes pharmacists as the agent of change for improving the rational use of medicines in the community. Community pharmacy is developing, albeit slowly, and is able to grasp a novel position to deliver pharmacy-related primary care services to the general public through new services, for example drug monitoring and home care. Nevertheless, integrating community pharmacy into primary care is relatively a new notion in the Indonesian setting, and is a challenging process given the presence of barriers in the macro, meso- and micro-level of practice.
APA, Harvard, Vancouver, ISO, and other styles
9

Alrasheedy, Alian A. "Pharmaceutical pricing policy in Saudi Arabia: findings and implications." Generics and Biosimilars Initiative Journal 9, no. 1 (March 15, 2020): 14–21. http://dx.doi.org/10.5639/gabij.2020.0901.003.

Full text
Abstract:
Introduction: Many countries have introduced policies and strategies to limit pharmaceutical expenditures. These include pharmaceutical pricing policies and related strategies to control medicine prices and to ensure appropriate and stable prices. The aim of this study was to provide an overview of the current pharmaceutical pricing policy for medicines in Saudi Arabia and to provide an evaluation of the impact of this policy on medicine prices. Methods: A description of the current pharmaceutical policy is presented by reviewing the current official documents and regulations related to pharmaceutical pricing in Saudi Arabia. A price comparison between the original brand medicines and their generic versions was conducted for the top six selling medicines in Saudi Arabia during the period of 2010–2015. Results: The findings showed that Saudi pharmaceutical pricing policy takes into consideration several factors including an international price benchmark, internal price referencing, and the price of the medicine in the country of origin when determining medicine prices. Based on this policy, there were large differences in the prices of generic medicines compared to original brand medicines. The generic medicine to original brand medicine price ratio was 0.87–0.30. However, the price of the first generic medicine was close to the price of original brand medicine, with the first generic medicine-to-original brand medicine price ratio was 0.87–0.81. In this study, there were large differences in the prices of generic medicines for the same molecule. In fact, price ratio among the generic medicines for the same molecule was between 0.96 and 0.18. However, some generic medicines imported from high income countries were cheaper than the medicines manufactured locally or manufactured in other countries in the Middle East. Conclusion: Medicine prices are strictly controlled through the pharmaceutical pricing policy in Saudi Arabia. Overall, the current policy has resulted in significant price differences among medicines, including medicines of the same molecule. Due to this large difference, the cost savings will depend on the product prescribed or procured by the health organization.
APA, Harvard, Vancouver, ISO, and other styles
10

Sepp, Kristiina, Anita Tuula, Veera Bobrova, and Daisy Volmer. "Primary health care policy and vision for community pharmacy and pharmacists in Estonia." Pharmacy Practice 19, no. 2 (May 2, 2021): 2404. http://dx.doi.org/10.18549/pharmpract.2021.2.2404.

Full text
Abstract:
Estonia, with a population of 1.3 million, is the smallest country in the three Baltic States. As a post-soviet country, Estonia over the past 30 years has built up a new health care system, including the pharmaceutical sector. The GDP allocated to cover health care costs is significantly lower in Estonia compared to the EU average. Despite this, Estonia has excelled in the development of digital e-services in healthcare at both the domestic and international levels. The development and integration of the Estonian community pharmacy sector into primary health care has been influenced and affected by the liberalization within pharmaceutical policy and the lack of cooperation with the rest of the health care sector. Community pharmacy ownership and location matters have been prevalent. The promotion of the pharmacy services has mostly taken place on the basis of a professional initiative, as cooperation with the state has not been active. Possibly the professional fragmentation of the pharmacy sector may have played a negative role. The community pharmacy network in Estonia, especially in cities, enables fast and convenient access to the pharmacy services. Community Pharmacy Service Quality Guidelines support the harmonization of the provided services and patient-centered concept to enhance the patient role and involvement in their care. In recent years, community pharmacies in Estonia have also offered various extended services that are more or less integrated with the primary health care system. New developments may be affected by frequent changes in legislation and a shortage of professional staff in community pharmacies. The ownership reform of pharmacies in 2020 has so far not had a significant impact on the operation of pharmacies or the quality of services provided.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Pharmaceutical policy. Pharmacy"

1

Snyder, Margie E., Caitlin K. Frail, Stephanie A. Gernant, Jennifer L. Bacci, Kim C. Coley, Lauren M. Colip, Stefanie P. Ferreri, et al. "Fellowships in Community Pharmacy Research: Experiences of Five Schools and Colleges of Pharmacy." Digital Commons @ East Tennessee State University, 2016. https://dc.etsu.edu/etsu-works/1479.

Full text
Abstract:
Objective To describe common facilitators, challenges, and lessons learned in 5 schools and colleges of pharmacy in establishing community pharmacy research fellowships. Setting: Five schools and colleges of pharmacy in the United States. Practice description: Schools and colleges of pharmacy with existing community partnerships identified a need and ability to develop opportunities for pharmacists to engage in advanced research training. Practice innovation: Community pharmacy fellowships, each structured as 2 years long and in combination with graduate coursework, have been established at the University of Pittsburgh, Purdue University, East Tennessee State University, University of North Carolina at Chapel Hill, and The Ohio State University. Evaluation: Program directors from each of the 5 community pharmacy research fellowships identified common themes pertaining to program structure, outcomes, and lessons learned to assist others planning similar programs. Results: Common characteristics across the programs include length of training, prerequisites, graduate coursework, mentoring structure, and immersion into a pharmacist patient care practice. Common facilitators have been the existence of strong community pharmacy partnerships, creating a fellowship advisory team, and networking. A common challenge has been recruitment, with many programs experiencing at least one year without filling the fellowship position. All program graduates (n = 4) have been successful in securing pharmacy faculty positions. Conclusion: Five schools and colleges of pharmacy share similar experiences in implementing community pharmacy research fellowships. Early outcomes show promise for this training pathway in growing future pharmacist-scientists focused on community pharmacy practice.
APA, Harvard, Vancouver, ISO, and other styles
2

Vernon, John A. "The economics of pharmaceutical research development : investment models, capital market imperfections and policy considerations." Thesis, City University London, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.367264.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Maahs, Michael Keith. "Medical Academia Conflict of Interest Policy and Potential Impact on Research Funding." ScholarWorks, 2015. http://scholarworks.waldenu.edu/dissertations/1317.

Full text
Abstract:
Medical Academia Conflict of Interest Policy and Potential Impact on Research Funding by Michael K. Maahs MPA, Troy University, 1993 BA, Ripon College, 1990 Dissertation Submitted in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Public Policy and Administration Walden University July 2015 The partnership between medical academia and the pharmaceutical industry has been scrutinized for issues associated with research bias. As a result of this scrutiny, the Institute of Medicine (IOM) issued policy recommendations in 2009 directing academia to adopt comprehensive conflict of interest (COI) policies. During the same time, a slowdown of funded research into academia occurred, and it is not clear whether the IOM recommendations contributed to this problem. The purpose of this case study was to determine the extent to which compliance with the IOM policy resulted in a reduction in funded research. The Advocacy Coalition Framework (ACF) was the theoretical lens used for study. COI policy statements (n = 15) were analyzed from American Association of Medical Colleges member schools that engage in medical research. In addition, in-depth interviews were conducted with 4 medical academic researchers. Data were inductively coded and organized around key themes. Key findings indicated that medical academia is compliant with IOM recommendations and COI policies did not appear to have a direct effect on research placement by industry. Interestingly, a possible explanation for reductions in industry funding relate to inefficient institutional review board processes. Additionally, the ACF construct was validated via an observed complex and slowly evolving COI policy process. The positive social change implications of this study include recommendations to academia to continue to monitor and report on COI and explore efficiency improvements related to IRB oversight in order to support important pharmaceutical research that ultimately improves the health and wellbeing of people.
APA, Harvard, Vancouver, ISO, and other styles
4

Hagemeier, Nicholas E., Daniel Ventricelli, and Rajkumar J. Sevak. "Situational Communication Self-Confidence Among Community Pharmacists: A Descriptive Analysis." Digital Commons @ East Tennessee State University, 2017. https://dc.etsu.edu/etsu-works/1481.

Full text
Abstract:
Objective: To compare community pharmacists' self-perceived communication confidence in prescription drug abuse and addiction (PDAA)-related scenarios to their self-confidence in other scenarios. Methods: An 18-item survey instrument adapted from the Self-Perceived Communication Competence instrument was administered to 2000 licensed Tennessee community pharmacists. Items elicited communication confidence across common community pharmacy scenarios. Analysis of communication self-confidence scores across context, receiver, audience, and demographic variables was conducted. Results: Mean self-confidence ratings ranged from 54.2 to 92.6 (0-100 scale). Self-perceived communication confidence varied across context, receiver, audience, personal and practice setting characteristics. Scenarios that involved PDAA communication with patients were scored significantly lower than non-PDAA patient scenarios (mean = 84.2 vs. 90.4, p Conclusion: Community pharmacists are less confident in their ability to communicate with patients about PDAA as compared to non-PDAA scenarios. Practice Implications: Engaging patients and prescribers in PDAA conversations is a critical component of preventing and treating PDAA. Research is warranted to further explore measures of situational communication self-confidence and interventions to optimize self-confidence beliefs across PDAA scenarios.
APA, Harvard, Vancouver, ISO, and other styles
5

Prather, April S. "ASSOCIATION BETWEEN DISPENSING CHANNEL AND CHRONIC OBSTRUCTIVE PULMONARY DISORDER EXACERBATIONS AMONG MEDICARE BENEFICIARIES." UKnowledge, 2018. https://uknowledge.uky.edu/pharmacy_etds/80.

Full text
Abstract:
Elderly patients with chronic obstructive pulmonary disease may be at increased risk of exacerbation due to physical and cognitive deficits that make proper inhaled medication adherence more difficult despite consistent medication access. This retrospective study utilized administrative medical and pharmacy claims data to examine the likelihood of having a COPD exacerbation requiring acute medical care by means of an emergency room visit or hospitalization in elderly patients receiving maintenance COPD medications from mail order and retail pharmacies. It was hypothesized that mail order patients would be more likely to experience exacerbations despite differences in medication access when compared to retail patients. The primary outcome of interest was exacerbation frequency expressed as the incidence density rate, and the secondary outcome was the proportion of days covered (PDC). The incidence rate ratio for acute exacerbations was not significantly different for mail order and retail groups, indicating patients using mail-order pharmacies were not significantly more likely to experience an exacerbation requiring acute medical care. Despite insignificant differences in incidence rates, mail order patients had significantly higher adherence rates.
APA, Harvard, Vancouver, ISO, and other styles
6

Brown, Shonda Dellena. "An Information Privacy Examination of the Practices of Pharmaceutical Companies Regarding Use of Information Collected Through Their Websites." NSUWorks, 2015. http://nsuworks.nova.edu/gscis_etd/47.

Full text
Abstract:
Consumers have begun to take a more proactive approach to their healthcare by accessing pharmaceutical companies Websites to obtain health and drug information, support groups, rebates, coupons, as well as free drug trials. In exchange for these benefits, companies require consumers to voluntarily disclose information. However, research has shown that consumers continue to be concerned about how their information is managed, used, and distributed by companies, especially if accessed via the Web. To date, there has been limited empirical research to examine the actual online practices of companies when it comes to privacy, especially those of pharmaceutical companies. Using Delphi expert panel process, the components of a benchmarking index were identified to examine the documented and actual online practices of 100 Website registrations with pharmaceutical companies. The evolution for the development of an index to measure the personal information privacy violations of pharmaceutical companies is presented. Second, empirical evidence is provided regarding the magnitude of voluntary adherence to the Fair Information Practices (FIPs) by pharmaceutical companies based upon the personal information privacy violations. The results revealed that companies with headquarters in Europe had fewer personal information privacy violations than those in Asia, UK, and the US. Moreover, the results indicate that fewer personal information privacy violations occur for chronic conditions than for non-chronic conditions, as well as fewer violations occur with Website registrations for updates than for discounts. Finally, both Europe and UK demonstrated more overall adherence to FIPs than the US and Asia. This suggests that self-regulation may not be sufficient, while more enforcement may be necessary to decrease personal information privacy violations.
APA, Harvard, Vancouver, ISO, and other styles
7

Vanghelof, Joseph C. "PNEUMOCOCCAL CONJUGATE VACCINE 13 COVERAGE IN CHILDREN, HIGH-RISK ADULTS 19-64 YEARS OF AGE, AND ADULTS OVER 65 YEARS OF AGE IN A COMMERCIALLY INSURED U.S. POPULATION." UKnowledge, 2017. http://uknowledge.uky.edu/pharmacy_etds/76.

Full text
Abstract:
This thesis aimed to elucidate the demographic characteristics associated with elevated or reduced rates of pneumococcal conjugate 13 (PCV13) vaccination. A retrospective cohort study was performed using the Truven Health MarketScan® Database. Three cohorts were created corresponding to populations for which the CDC recommends PCV13 vaccination. Cohort 1: children < 36 months of age. Cohort 2: adults 19-64 years of age with high infection risk. Cohort 3: adults > 65 years of age. Odds of having a PCV13 claim were calculated for each cohort. For Cohort 1, 78% out of a total of 353,214 subjects had a sufficient number of PCV13 doses to meet CDC recommendations. For Cohort 2, 3.7% out of a total of 673,157 subjects had a PCV13 claim. For Cohort 3, 18% of 1,262,531 subjects had a PCV13 claim. Odds of vaccination were generally lower in younger subjects, those with fewer outpatient claims, and those with residence in the Northeast and South regions. In Cohort 2, odds were reduced in subjects with generalized malignancy. Gender and urban residence were poor predictors of vaccination status. By understanding the demographic factors associated with lower rates of vaccination, clinicians may more effectively direct their efforts to increase pneumococcal vaccination coverage.
APA, Harvard, Vancouver, ISO, and other styles
8

Hagemeier, Nicholas E., Ivy A. Click, Heather Flippin, Holly Gilliam, Alexandra Ross, Jeri Ann Basden, and Ronald Carico. "Pharmacists’ and Prescribers’ Neonatal Abstinence Syndrome (NAS) Prevention Behaviors: A Preliminary Analysis." Digital Commons @ East Tennessee State University, 2017. https://dc.etsu.edu/etsu-works/1483.

Full text
Abstract:
Background Maternal opioid use and neonatal abstinence syndrome (NAS) incidence have increased markedly in the US in recent years. Objectives (1) To assess prescribers’ and community pharmacists’ guideline-based NAS prevention behaviors; (2) to describe providers’ perceptions of contraceptive appropriateness in female patients of childbearing age. Method Cross-sectional study of 100 randomly selected primary care physicians, 100 prescribers authorized to engage in in-office treatment of opioid use disorders with buprenorphine, 100 pain management clinic directors, and 100 community pharmacists in Tennessee (N = 400 providers total) to evaluate self-reported engagement in 15 NAS prevention behaviors and perceived appropriateness of 8 contraceptive methods in opioid using women of childbearing age. Results An overall response rate of 17.5% was obtained. Pain clinic directors reported the most engagement in NAS prevention, engaging 80% or more of female patients of childbearing age prescribed an opioid in 11 prevention behaviors, followed by buprenorphine prescribers (8 behaviors), primary care physicians (5 behaviors), and community pharmacists (2 behaviors). Pain clinic directors, primary care physicians, and community pharmacists perceived oral contraceptive pills and patches to be as appropriate as long-acting, reversible forms of contraception (e.g., implants, injectable depots, intrauterine devices). Conclusion Provider engagement in behaviors that could prevent NAS is variable. Interventions should be implemented that equip providers to engage patients in conversations about long-acting, reversible contraception.
APA, Harvard, Vancouver, ISO, and other styles
9

Mora, Cole. "A Tough Pill to Swallow: PhRMA and Pharmaceutical Lobbying in the Context of the Affordable Care Act." Scholarship @ Claremont, 2017. http://scholarship.claremont.edu/cmc_theses/1544.

Full text
Abstract:
What is lobbying, properly understood, in the United States, and what strategies and tactics—including and especially those determined by contextual factors, as well as firm characteristics—are commonly employed by corporate lobbies as they operate in our American political environments? Considering this, what are the main strategies and tactics employed by the pharmaceutical lobby, with a particular focus on the Pharmaceutical Manufacturers and Researchers of America, or PhRMA? Finally, what roles did PhRMA play in the development and passage of the Obama administration’s Affordable Care Act, and what can this tell us about the lobbying strategies and tactics utilized by one of the most effective lobbies in modern times, as well as about how their strategies and tactics align, or not, with conventional conceptions of lobbying? Through effective use of key lobbying tactics such as direct lobbying and use of public awareness, PhRMA completed one of the more successful lobbying campaigns in recent history. When the White House came calling, they were first to the table, for they knew that with that seat came a position of leverage. From there, they were able to build both political and public support to complete a deal with the Obama administration that they positioned as necessary to keep the Affordable Care Act alive. This deal would ensure that the pharmaceutical industry would pay a flat rate of support for the act, and was therefore guaranteed protection from future government attempts to set or regulate the prices of their products and medicines. PhRMA played the long game, and they played it well.
APA, Harvard, Vancouver, ISO, and other styles
10

Kennedy, Kenneth Neil. "INFLUENCE OF ONCOTYPE DX® ON CHEMOTHERAPY PRESCRIBING IN EARLY STAGE BREAST CANCER PATIENTS: A CLAIMS-BASED EVALUATION OF UTILIZATION IN THE REAL WORLD." UKnowledge, 2012. http://uknowledge.uky.edu/pharmacy_etds/11.

Full text
Abstract:
The decision for adjuvant therapy in women with early stage breast cancer (ESBC) has historically been guided by the presence or absence of specific biological markers (hormone and HER2 receptors), age, and extent of nodal involvement. Oncotype DX® is a validated assay that quantifies protein expression that can predict the risk of cancer recurrence. This study evaluates if the use of Oncotype DX® impacts chemotherapy prescribing in ESBC. This retrospective, cohort study identified patients with ESBC from a large commercially insured population from January 2007 through June 2009. Patients were identified as having ESBC by utilizing procedure and diagnosis codes to indicate that a sentinel lymph node biopsy had been performed. Hormone receptor status was verified by patients receiving at least one month of hormonal therapy including: tamoxifen, anastrozole, letrozole, or exemestane. Exclusion criteria will include patients less than 18 years of age, procedure codes indicating axillary lymph node dissection, or charges for trastuzumab. The administration of Oncotype DX® was not found to significantly affect a physician’s decision to prescribe chemotherapy. However, there were significant regional differences in Oncotype DX® utilization by region. Future studies should be conducted at a population level to determine the effects of Oncotype DX®.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Pharmaceutical policy. Pharmacy"

1

Division, Botswana Pharmaceutical Services. Pharmacy practice standards 2002. Gaborone?: Ministry of Health?, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Commission of the European Communities. Pharmaceutical sector: Coordinated instruments. Luxembourg: Office for Official Publications of the European Communities, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Aparasu, Rajender R. Research methods for pharmaceutical practice and policy. London: Pharmaceutical Press, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Abbott, Frederick M. Global pharmaceutical policy: Ensuring medicines for tomorrow's world. Cheltenham, UK: Edward Elgar, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

G, Dukes M. N., ed. Global pharmaceutical policy: Ensuring medicines for tomorrow's world. Cheltenham, UK: Edward Elgar, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Colloque DPHM-INSERM (4th 1990 Paris, France). L' Europe du médicament: Réalités et ambitions : 4e colloque DPHM-INSERM, 26-29 novembre 1990, Paris-CNIT (La Défense). Paris: Ministère des affaires sociales et de la solidarité, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Le médicament, enjeu du XXIe siècle: Le temps des alliances. Paris: le Cherche midi, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Valverde, José Luis. New developments of pharmaceutical law in the EU. Amsterdam: IOS Press, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ŭiyak punŏp chŏngchʻaek kwajŏng. Kyŏnggi-do Pʻaju-si: Chimmundang, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Carrin, Guy. Self-financing of drugs in developing countries: The case of the public pharmacy in Fianga (Chad). Antwerpen, Belgium: Centre for Development Studies, University of Antwerp, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Pharmaceutical policy. Pharmacy"

1

Malik, Iram, Muhammad Atif, Shane L. Scahill, and Zaheer-Ud-Din Babar. "Pharmacy Practice and Policy Research in Pakistan: A Review of Literature Between 2014 and 2019." In Global Pharmaceutical Policy, 139–75. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-2724-1_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Cohen, Perry, and Mary Wohletz. "Managed Care Pharmacy and Pharmacy Benefit Management." In Pharmaceutical Public Policy, 303–19. CRC Press, 2016. http://dx.doi.org/10.1201/b19633-20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Subramaniam, Vaiyapuri, and Michael Valentino. "Department of Veterans Affairs Pharmacy Programs." In Pharmaceutical Public Policy, 441–62. CRC Press, 2016. http://dx.doi.org/10.1201/b19633-28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Jones, John. "Managed Care Pharmacy." In Handbook of Pharmaceutical Public Policy, 227–46. CRC Press, 2007. http://dx.doi.org/10.1201/b14469-14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Chiappelli, Theodore. "Public Health Pharmacy." In Handbook of Pharmaceutical Public Policy, 109–20. CRC Press, 2007. http://dx.doi.org/10.1201/b14469-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Babar, Zaheer-Ud-Din, and Shane L. Scahill. "Pharmaceutical Policy." In Social and Administrative Aspects of Pharmacy in Low- and Middle-Income Countries, 419–37. Elsevier, 2018. http://dx.doi.org/10.1016/b978-0-12-811228-1.00025-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Heath, W. "The Department of Defense Pharmacy Programs." In Handbook of Pharmaceutical Public Policy, 137–48. CRC Press, 2007. http://dx.doi.org/10.1201/b14469-10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Madigan, Melissa, and Ed Rickert. "State versus Federal Regulation of Pharmacy." In Handbook of Pharmaceutical Public Policy, 171–90. CRC Press, 2007. http://dx.doi.org/10.1201/b14469-12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Valentino, Michael, and Jonathan Perlin. "Department of Veterans Affairs Pharmacy Programs." In Handbook of Pharmaceutical Public Policy, 121–36. CRC Press, 2007. http://dx.doi.org/10.1201/b14469-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Nguyen, Tuan A., and Elizabeth E. Roughead. "Strengths and Weaknesses of Pharmaceutical Policy in Relation to Rational and Responsible Medicines Use." In Social and Administrative Aspects of Pharmacy in Low- and Middle-Income Countries, 247–62. Elsevier, 2018. http://dx.doi.org/10.1016/b978-0-12-811228-1.00015-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pharmaceutical policy. Pharmacy"

1

Ibrahim, Meram, Banan Mukhalalati, Majdoleen Al alawneh, and Ahmed Awaisu. "Qatar National Vision 2030." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0226.

Full text
Abstract:
Introduction: The United Nations launched the Sustainable Development Goals in 2015. One of these goals describes achieving a Universal Health Coverage by 2030. This signifies workforce planning in healthcare professions (United Nations, 2015). The International Pharmaceutical Federation (FIP) published reports about pharmacy workforce planning in several countries. However, data about Qatar was not included in these reports. In 2017, FIP developed a transformational roadmap of pharmaceutical workforce and education. One component of the roadmap is the Pharmaceutical Workforce Development Goals (PWDGs) (International Pharmaceutical Federation, 2016). This research aims to conduct a self-assessment of the pharmaceutical workforce and education in Qatar in relation to the FIP’s PWDGs. This will be followed by prioritization of the identified gaps and recommendation of measures to address them. Methods: Three rounds of conventional Delphi technique (Hasson et al., 2000) are conducted with expert panels in the College of Pharmacy at Qatar University and the Ministry of Public Health, utilizing the FIP’s self-assessment survey. Content analysis is used to analyse and prioritize the identified gaps. Results: The lack of competency framework (PWDG5), workforce data (PWDG12), and workforce policy formation (PWDG13) are the three major gaps in the provision of pharmaceutical workforce and pharmacy education in Qatar, influencing other PWDGs. These gaps need to be addressed by the formation of Qatari Pharmaceutical Association through which academic, practice, and policymaking sectors can work together in developing a health workforce intelligence system. Conclusion: The results indicated that PWDGs are interrelated and a gap in one goal can negatively influence others (Bruno et al., 2018). Results and recommendations of this research will facilitate the implementation of strategic plans across leading pharmacy sectors to meet health needs in Qatar and achieve the third pillar of the Qatar National Vision 2030 “A Healthy Population: Physically and Mentally” (General Secretariat for Development, 2008).
APA, Harvard, Vancouver, ISO, and other styles
2

JACHOWICZ, Michał. "Legal Status of a Pharmacist as a Participant of the Pharmacy Market in Poland." In Current Trends in Public Sector Research. Brno: Masaryk University Press, 2020. http://dx.doi.org/10.5817/cz.muni.p210-9646-2020-6.

Full text
Abstract:
The provision of the pharmaceutical service is the basic designation of the pharmacy activities as a public health care facility and is a correlate of the subjective right to health care guaranteed under the Polish Constitution. The provision of the pharmaceutical service remains within the scope of the profession of a pharmacist as a profession of public trust, which is also a regulated profession. Taking into account the need to ensure the highest level of implementation of the right to health care, the legal status of a pharmacist as a participant in the pharmacy market should be subject to special legal protection. The assessment of the existing legal status in this respect remains justified by both the subjective distinction between categories of entrepreneurs who hold a permit to operate a generally accessible pharmacy, as well as the legislative process on principles of fulfilling the pharmacist's professional obligations included in the draft Act on the profession of pharmacist. The purpose of this article is to assess the indicated legal conditions undertaken both on the basis of the existing legal status and proposed statutory solutions.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Pharmaceutical policy. Pharmacy' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography